Ariad Pharmaceuticals Inc. provided positive clinical data for Iclusig (ponatinib). The drug had a rocky start after receiving a December 2012 approval for use in patients with chronic, accelerated and blast phases of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) whose disease is resistant or intolerant to tyrosine kinase inhibitors (TKIs).